This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent. Top assignees: Ludwig Institute for Cancer Research Limited, Ucl Business Plc. Active years: 2014.
Company Filing History:
1 out of 530 
1 out of 299 
Years Active: 2014
Title: Ivan Nemazanyy: Innovator in mTOR Research
Introduction
Ivan Nemazanyy is a notable inventor based in London, GB. He has made significant contributions to the field of molecular biology, particularly in the study of the mammalian target of rapamycin (mTOR) protein. His innovative work has implications for understanding and treating various diseases.
Latest Patents
Ivan Nemazanyy holds a patent for a truncated variant of the mammalian target for rapamycin (mTOR) protein. This invention relates to mTORbeta, a splice form of mTOR, along with nucleic acids encoding mTOR beta and antibodies against mTOR beta. The patent also covers methods for producing mTOR beta and screening for agents that modulate mTOR beta expression and/or activity. Furthermore, it includes a method for treating diseases associated with aberrant expression of mTOR beta through the administration of agents that alter mTOR activity and/or expression. He has 1 patent to his name.
Career Highlights
Throughout his career, Ivan has worked with prominent organizations such as UCL Business Plc and the Ludwig Institute for Cancer Research Limited. His experience in these institutions has allowed him to advance his research and contribute to significant scientific discoveries.
Collaborations
Ivan has collaborated with notable colleagues, including Ganna Panasyuk and Alexander Zhyvoloup. These partnerships have enriched his research endeavors and fostered innovation in the field.
Conclusion
Ivan Nemazanyy is a distinguished inventor whose work on mTORbeta has the potential to impact medical science significantly. His contributions to the understanding of mTOR protein and its implications for disease treatment highlight the importance of innovation in research.